Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
HU

NASDAQ · HUMAW

Humacyte, Inc.

Healthcare · Biotechnology

$0.00

Down-$0.00 (-78.05%)

Updated Sep 13, 2026, 10:15 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
161.53M
P/E ratio
-10.7
Dividend yield
0.00%
52-week range
$0.00 – $0.13
Volume
258.66K
Avg. volume
20.94K

Price performance

HUMAW price history

1M range · 7 trading sessions · Daily adjusted prices

HUMAW closed at $0.00 after 7 trading sessions, down 87.84% for the selected period.

Last close
$0.00
Period change
-87.84%
Period low
$0.00
Period high
$0.01
Daily close
View OHLC price history
HUMAW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 25, 2026$0.0039$0.0039$0.0009$0.0009258.66K
Aug 24, 2026$0.005$0.005$0.0025$0.004158.66K
Aug 21, 2026$0.009$0.009$0.005$0.005117.34K
Aug 20, 2026$0.009$0.009$0.0052$0.0097.96K
Aug 19, 2026$0.0074$0.0089$0.0051$0.008723.88K
Aug 18, 2026$0.0054$0.0054$0.0054$0.0054260
Aug 17, 2026$0.0053$0.0075$0.0053$0.007421.02K

Latest HUMAW news

The latest Smart Investors Daily articles mentioning HUMAW.

Stock researchCompany · Overview

HUMAW research

Overview

Company profile and research snapshot.

Company profile

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 13, 2026

Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds

Humacyte earnings update and stock context Humacyte (HUMA) reported second quarter 2026 results that included revenue of US$0.406 million and a net loss of US$36.8 million, alongside recent Nasdaq compliance pressure after its share price stayed below US$1.00. For the first half of 2026, the company reported revenue of US$0.901 million and a net loss of US$54.42 million. Earnings per share moved from a small profit a year ago to a basic loss of US$0.25 from continuing operations. Humacyte...

Yahoo · Aug 13, 2026

Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall

Humacyte stock has had a very rough run over the last several years, and current valuation checks now lean toward the shares looking expensive rather than like a clear bargain. Humacyte has declined 93.3% over the past 5 years, which puts recent pricing in the context of a very long and deep drawdown for existing shareholders. Recent progress in tissue engineered vessel programs and regulatory milestones may support expectations for future revenue, while the risk that clinical or regulatory...

Yahoo · Aug 13, 2026

Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women

Humacyte (NasdaqGS:HUMA) reported Phase 3 dialysis access data showing its acellular tissue engineered vessel outperformed standard of care for female patients. The company plans to file a supplemental Biologics License Application based on the female cohort results from the dialysis access trial. The FDA accepted an Investigational New Drug application for Humacyte’s new coronary vessel candidate, allowing clinical development to proceed. This progress at Humacyte is part of a wider push...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By